Zacks Research Brokers Increase Earnings Estimates for REVB

Revelation Biosciences, Inc. (NASDAQ:REVB) – Zacks Research lifted their Q3 2026 earnings estimates for Revelation Biosciences in a research note issued on Friday, August 7th. Zacks Research analyst B. Sorensen now expects that the company will earn ($0.82) per share for the quarter, up from their previous forecast of ($0.83). The consensus estimate for Revelation Biosciences’ current full-year earnings is ($5.20) per share. Zacks Research also issued estimates for Revelation Biosciences’ Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($5.17) EPS and FY2027 earnings at ($2.36) EPS.

Separately, Weiss Ratings cut Revelation Biosciences from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Revelation Biosciences Trading Down 1.8%

NASDAQ REVB opened at $1.11 on Wednesday. The firm’s 50 day simple moving average is $1.05 and its 200 day simple moving average is $1.22. The firm has a market capitalization of $4.34 million, a price-to-earnings ratio of -0.09 and a beta of -0.15. Revelation Biosciences has a 1 year low of $0.88 and a 1 year high of $11.72.

Revelation Biosciences (NASDAQ:REVB) last issued its earnings results on Friday, August 7th. The company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Armistice Capital LLC acquired a new stake in shares of Revelation Biosciences in the 3rd quarter valued at approximately $114,000. Geode Capital Management LLC acquired a new position in Revelation Biosciences during the 4th quarter worth approximately $27,000. Finally, Sabby Management LLC increased its position in Revelation Biosciences by 192.5% during the 4th quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock worth $484,000 after purchasing an additional 398,651 shares in the last quarter. Institutional investors own 12.80% of the company’s stock.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.